Xintela ABFNSE Xintela Stock Report

Xintela AB engages in the development of pharmaceutical products. The company is headquartered in Lund, Skane. The company went IPO on 2016-03-22. In the field of regenerative medicine, the Company focuses on cartilage damage and osteoarthritis, and in the field of brain tumors, its focuses on the development of a treatment for glioblastoma, an aggressive tumor. The firm has developed therapeutic antibodies, which bind to cancer cells. The company has also developed XINMARK, a marker technology which consists of specific proteins, which work as recognition flags on the surface of certain cells. The markers make it possible to identify and select certain types of stem cells which can develop into cartilage cells.